Envista Holdings Co. (NYSE:NVST) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG raised its stake in Envista Holdings Co. (NYSE:NVST) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,521 shares of the company’s stock after purchasing an additional 4,008 shares during the quarter. Deutsche Bank AG owned about 0.07% of Envista worth $2,306,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVST. Lecap Asset Management Ltd. acquired a new stake in shares of Envista in the fourth quarter valued at about $281,000. Hantz Financial Services Inc. boosted its holdings in Envista by 146.6% in the 4th quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company’s stock worth $2,131,000 after acquiring an additional 65,679 shares during the period. Norges Bank purchased a new position in Envista in the 4th quarter worth approximately $38,052,000. Natixis Advisors LLC grew its position in Envista by 1.8% in the fourth quarter. Natixis Advisors LLC now owns 106,652 shares of the company’s stock valued at $2,057,000 after acquiring an additional 1,845 shares in the last quarter. Finally, Lightrock Netherlands B.V. purchased a new stake in shares of Envista during the fourth quarter valued at approximately $5,193,000.

Analysts Set New Price Targets

NVST has been the subject of several analyst reports. Wells Fargo & Company set a $19.00 target price on shares of Envista in a research note on Saturday, March 8th. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday, March 6th. Bank of America lowered their target price on Envista from $26.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. JPMorgan Chase & Co. dropped their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Finally, New Street Research set a $19.00 price target on Envista in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Envista currently has an average rating of “Hold” and an average target price of $20.08.

Envista Stock Performance

Shares of NYSE NVST opened at $16.84 on Friday. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $16.57 and its two-hundred day moving average price is $18.88. Envista Holdings Co. has a 52-week low of $14.22 and a 52-week high of $23.00. The stock has a market capitalization of $2.85 billion, a P/E ratio of -2.59, a P/E/G ratio of 1.27 and a beta of 0.97.

Envista (NYSE:NVST) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.04. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. The business had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. During the same quarter in the previous year, the firm posted $0.26 EPS. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.